Answers are grounded in this paper and cite their sources.
Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery. Overall survival did not differ significantly between the groups in this analysis. (Funded by Merck Sharp and Dohme; KEYNOTE-671 ClinicalTrials.gov number, NCT03425643.).
No takes yet. Share an insight, caveat, or question.
Wakelee et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: